WEGOVY

Launch

semaglutide

NDAORALTABLET
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Glucagon-like Peptide-1 (GLP-1) Agonists

Pharmacologic Class:

GLP-1 Receptor Agonist

Clinical Trials (5)

NCT07411378Phase 2Not Yet Recruiting

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Started Jul 2026
NCT07423481N/ANot Yet Recruiting

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

Started Jun 2026
3,000 enrolled
Obesity & Overweight
NCT07400107Phase 3Not Yet Recruiting

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Started May 2026
1,000 enrolled
ObesityOverweightDiabetes Mellitus, Type 2
NCT07317115N/ARecruiting

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

Started Mar 2026
NCT05689372N/ANot Yet Recruiting

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Started Feb 2026
600 enrolled
Diabetes Mellitus, Type 2

Loss of Exclusivity

LOE Date
Feb 1, 2039
157 months away
Patent Expiry
Feb 1, 2039
Exclusivity Expiry
Dec 22, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
8536122
Mar 20, 2026
SubstanceProduct
8129343
Dec 5, 2031
SubstanceProduct
9278123
Dec 16, 2031
Product
U-4389
11382957
Dec 16, 2031
Product
10278923
May 2, 2034
U-4389